FindTrial
Sign In

Pilot study of Hycamtin in combination with Cisplatin

Phase I/II clinical pilot study of Hycamtin in combination with Cisplatin for extensive-disease small cell lung cancer

Status
Unknown
Phases
Phase 2
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT2080220961
Enrollment
Unknown
Registered
2010-01-13
Start date
2010-01-13
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Small cell lung cancer

Interventions

investigational material(s) Generic name etc : Hycamtin INN of investigational material : Therapeutic category code : 424 Antineoplastic preparations extracted from plants Dosage and Administration f

Sponsors

Nippon Kayaku Co., Ltd.
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1) Histological or cytological diagnosis of SCLC 2) Measurable disease 3) Adequate organ function 4) ECOG Performance Status 0-1 5) Life expectancy at least 3 months 6) Written informed consent

Exclusion criteria

Exclusion criteria:

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026